Lawsuit Filed Against Regencell Bioscience Holdings by Pomerantz Law Firm Raises Concerns

Pomerantz Law Firm Files Class Action Against Regencell Bioscience Holdings

Pomerantz LLP has initiated a class action lawsuit against Regencell Bioscience Holdings Limited, as well as certain of its officers. The lawsuit, filed in the United States District Court for the District of Maryland, highlights serious concerns regarding potential securities law violations and the management of the company, especially during a pivotal class period from October 28, 2024, to October 31, 2025.

Overview of the Allegations

The class action extends to all individuals and entities, excluding defendants, who acquired Regencell securities during the specified period. Plaintiffs are seeking to recover damages attributed to the alleged violations of federal securities laws, as far as the Securities Exchange Act of 1934 is concerned. If investors purchased Regencell securities during this timeframe, they have until June 23, 2026, to apply for the role of Lead Plaintiff in this class action.

At the heart of the allegations is Regencell’s marketing as a bioscience company focused on traditional Chinese medicine (TCM) aimed at treating ADHD and ASD—disorders deemed generally incurable by modern medicine. Regencell claims that while existing treatments simply alleviate symptoms, their TCM approach targets the root causes. However, these assertions have come under scrutiny.

Company Background and Market Performance

Regencell is classified as a controlled company, with the management owning a significant percentage of its shares. A staggering 88.8% of its shares were reported to be held by its directors and executive officers, underscoring the centralized control within the company, primarily by its founder, Yat-Gai Au. Interestingly, during the early stages of the class period, the company's shares traded at remarkably low prices, staying below 30 cents.

However, a dramatic change occurred starting in May 2025 when the stock price skyrocketed, peaking at $78.00 by mid-June—a staggering 48,650% increase from the beginning of the class period. Yet, just weeks later, the stock plummeted back down to around $20.00, revealing significant volatility.

What raises further concern is Regencell's lack of fundamental business metrics; the company has not reported any approved products or revenue, and has incurred losses since its inception. Furthermore, their research and development funding did not align with industry standards for a company purporting to develop new medicinal treatments, raising questions about their operational viability.

Market Manipulation Claims

The lawsuit emphasizes that Regencell’s rapid stock fluctuations may not be merely a reflection of its company performance but rather indicative of potential market manipulation and vulnerabilities. Allegedly, during the class period, defendants made misleading statements regarding the company's operations and risk factors, contributing to the inflated stock prices.

There are claims from investors that the company downplayed the reality of its market exposure and operational stability. These misleading communications may have left investors facing significant financial risk.

Developments and Further Investigations

The situation took a critical turn on October 31, 2025, when Regencell disclosed an ongoing investigation by the U.S. Department of Justice (DOJ) concerning the trading of its ordinary shares. The DOJ's inquiry, which involves document production related to corporate operations, raised red flags among investors, leading to a further decline in stock prices.

As of November 3, 2025, Regencell shares saw a fall of 18.56%, a clear reflection of the growing uncertainty surrounding the company. This significant drop indicates the escalating concerns regarding both financial stability and regulatory compliance.

Conclusion

Pomerantz Law Firm, with its well-established history in handling securities-related class actions, aims to address the grievances of investors who might be affected by the alleged misconduct surrounding Regencell. Given the complexities of securities law and the implications of this class action, developments from this lawsuit will be closely monitored by the market and legal analysts alike.

For more information or to express interest in joining the class action, affected parties can reach out to Pomerantz LLP through contact information provided in their announcement.

Pomerantz LLP is renowned in the landscape of class action litigation and remains committed to advocating for the rights of investors.